NMN and NR: uses, evidence, dosing and safety

NMN and nicotinamide riboside are the flagship products of the longevity supplement industry, and they present an unusual problem: the mechanism works.

Take them and a molecule called NAD+ rises in your blood, reliably, by two or three times. That is not marketing, it is measured in trial after trial. The difficulty is what happens next, which is mostly nothing.

What NMN and NR are, and why they are sold together

Both are precursors to NAD+, nicotinamide adenine dinucleotide, a molecule every cell uses to run its energy metabolism and its DNA repair machinery. NAD+ levels fall with age, and that observation is the foundation of the entire category.

NMN is nicotinamide mononucleotide. NR is nicotinamide riboside. They enter the same pathway at slightly different points and are usually discussed together, which is why this page covers both.

Chemically, they are close relatives of vitamin B3. That is not a rhetorical jab: it is how regulators classify them, as the next section shows.

How NMN and NR work

NAD+ cannot be taken directly in useful amounts, so the strategy is to supply a precursor the body can convert.

That strategy works. NMN availability is a rate-limiting factor in mammalian NAD+ biosynthesis, meaning it is the bottleneck, so adding more of it raises output.

In mice, restoring NAD+ improves a long list of things: metabolic function, muscle performance, measures of aging. In rodents, obesity and aging impair nicotinamide adenine dinucleotide (NAD+) biosynthesis, which contributes to metabolic dysfunction.

The human question is whether the same chain holds: precursor raises NAD+, and raised NAD+ makes a person better. The first link is solid. The second is where the evidence sits.

What the evidence says about NMN, NR and NAD+ levels

Start with what works, because it genuinely does.

In a trial of nicotinamide riboside in people with mild cognitive impairment, blood NAD+ increased twofold in the NR group.

In a separate long COVID trial, NAD+ levels increased by 2.6- to 3.1-fold after 5-10 weeks of supplementation, and remained elevated at 20 weeks, while in the placebo group NAD+ levels remained close to baseline.

Two different compounds, two different populations, the same answer. These products do the biochemical thing they claim.

What the evidence says about NMN, NR and cognition

Here the chain breaks, and it breaks in the most informative way possible.

The mild cognitive impairment trial had cognition as its primary outcome. Forty-two participants completed the study, and the result was blunt: there were no improvements in cognitive function (primary outcome), total CBF, or blood pressure (secondary outcomes), CBF being cerebral blood flow.

The authors’ summary is the sentence that defines this whole category. NR effectively raises NAD+ in people with MCI but does not improve cognitive function, total CBF, or blood pressure over 12 weeks.

The mechanism worked and the person did not get better. Exploratory analyses revealed potential increases in regional CBF, particularly in the hippocampus, which is a lead for the next trial rather than a result.

What the evidence says about NMN and metabolic health

This is the strongest positive human finding the category has.

A 10-week, randomized, placebo-controlled, double-blind trial gave NMN to postmenopausal women with prediabetes who were overweight or obese.

Insulin-stimulated glucose disposal, assessed by using the hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling increased after NMN supplementation but did not change after placebo treatment. The clamp is the reference method for measuring insulin sensitivity, so this is a rigorous measurement rather than a soft one.

Three limits keep it in proportion. It is one trial in one narrow group, chosen because they were metabolically impaired to begin with. The outcome is a laboratory measure of how muscle handles glucose, not a diagnosis avoided. And ten weeks is short.

It is a real result. It is not evidence that a healthy person taking NMN will avoid diabetes.

What the evidence says about NMN and exercise recovery

A small human muscle study is worth including because it complicates the assumption that more NAD+ is simply better.

Researchers looked at muscle after blood-flow-restricted exercise and found that NMN supplementation, while inhibiting inflammatory signaling in exercised human skeletal muscle, may also suppress mitochondrial replenishment from phagocytes to repairing myofibers.

Put simply, it damped the inflammation that follows hard exercise, and in doing so appeared to interfere with a repair process that delivers new mitochondria to damaged muscle fibers.

That is a single mechanistic study and should not be over-read. But it is a concrete example of why blunting a stress response is not automatically a benefit, which is the same trap antioxidant supplements fell into.

Myths about NMN and NR, and what the evidence says

“It reverses aging.” No human trial has measured aging, lifespan or healthspan as an outcome. The lifespan work is in mice.

“It raises NAD+, and NAD+ falls with age, so it must help.” The first two clauses are true and the third does not follow. The MCI trial raised NAD+ twofold and changed nothing measurable.

“It is proven for metabolic health.” One trial, in prediabetic postmenopausal women, on a laboratory measure. That is a promising start, not a proof.

“NMN is better than NR” or the reverse. No adequately powered head-to-head trial has settled this. Choosing between them is choosing between marketing claims.

“Regulators recognise it as an anti-aging compound.” EFSA assessed it as a source of niacin, which is vitamin B3.

Dosing and forms of NMN and NR

Human trials have used roughly 250 to 900 mg a day of NMN and comparable ranges of NR. The Science trial used 250 mg daily, and a dose-ranging trial covered daily NMN (300, 600, or 900 mg) or placebo.

EFSA’s assessment covers use as a source of niacin up to 300 mg/day of beta-NMN, noting that the proposed maximum intake corresponds to 109.7 mg/day of nicotinamide, which is approximately five times the population reference intake (PRI) of niacin for adults but remains below the upper level (UL) of 900 mg/day for nicotinamide.

There is no established optimal dose, because there is no established outcome to optimize for.

Safety, side effects and who should be careful

Short-term safety looks reasonable. EFSA reports that the identity, production process, composition and specifications of the NF do not raise safety concerns and that no concerns were identified regarding genotoxicity. Trials report no serious adverse effects.

Two things temper that. Trials run 10 to 20 weeks, so nothing is known about years of use, which is precisely how these products are sold. And the long COVID trial saw substantial dropout in the treatment arm: there was a 32.4% and 51.4% dropout in the NR-NR group at 10 weeks and 20 weeks, respectively, vs. 14.3% dropout at each timepoint in the PBO-NR group. That is a tolerability signal even where it is not a safety one.

The muscle study above is a reminder that suppressing a normal stress response can have costs that a blood test will not show.

EFSA’s assessment excludes pregnant and lactating women, and anyone with a medical condition or on medication should treat this like any other unproven supplement and ask first.

Interactions

No major drug interactions are established, which reflects how little is known rather than a clean record.

Because these compounds are metabolically related to niacin, anyone already taking high-dose niacin for cholesterol should mention it, so the total nicotinamide load is accounted for.

Bottom line on NMN and NR

If you want a supplement that reliably changes a biomarker, this category delivers. NAD+ goes up, measurably, every time.

If you want a supplement that has been shown to make people healthier, the evidence is not there yet. The one trial with a solid positive result improved a laboratory measure of insulin sensitivity in prediabetic women over ten weeks. The trial that tested whether raised NAD+ improves thinking found it did not.

The honest summary is that this is an interesting biological hypothesis with a large market attached and a thin human outcome record. It may work out. Right now, the strongest claim supportable by human evidence is that these products are an expensive way to take vitamin B3, which is also how Europe’s food safety regulator classifies them.